Bayer markets $14.2B loan for Merck consumer unit; Adcock sinks in H1; CIA ditches vaccination ruses;

@FiercePharma: Top-read on FiercePharma Mon: How did AstraZeneca make the Pfizer bid a Harry vs. Voldemort story? Story | Follow @FiercePharma

@TracyStaton: Some $AZN investors are balking at the board's $PFE snub. Others are practically high-fiving Chairman Johannson. More from Reuters | Follow @TracyStaton

@EricPFierce: FDA inspectors find 10 trash bags of partially destroyed raw data CGMP records at Sun Pharma plant. Article via FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: Kymab, Gates Foundation to team up for malaria, HIV antigen discovery. More from FierceVaccines | Follow @CarlyHFierce

> Bayer is marketing a $14.2 billion loan backing its proposed buyout of Merck's ($MRK) consumer unit. Report

> The U.K.'s cost watchdog has recommended Johnson & Johnson's ($JNJ) Type 2 diabetes med Invokana for use in Britain's National Health Service. More

> South Africa's Adcock Ingram blamed an H1 loss on costs related to a failed takeover by Chile's CFR. Report

> Takeda execs hid the cancer risks of diabetes med Actos to protect billions of dollars in sales, a lawyer for two women argued in closing arguments in a Las Vegas trial. More

> Jazz Pharmaceuticals ($JAZZ) has named Russell Cox as its COO. Release

> Merck KGaA is investing €50 million ($68.5 million) in its Italian production site in Bari. Release (PDF)

Medical Device News

@FierceMedDev: Medtronic and Edwards Lifesciences settle the score in ongoing patent feud. More | Follow @FierceMedDev

@VarunSaxena2: Device companies win in survey of top places to work in medical sales. 53% of respondents prefer them. Story (reg. req.) | Follow @VarunSaxena2

@MichaelGFierce: From Harvard: Herpes-loaded stem cells used to kill brain tumors. News | Follow @MichaelGFierce

@EmilyWFierce: "Drinkable books" double as a water filter, educate developing world about deadly waterborne illnesses. More | Follow @EmilyWFierce

> FDA approves iPad-based blood loss monitor. Item

> HistoSonics banks $14M for ultrasound prostate tech. More

> Medtronic's earnings plunge 54% due to litigation charge. Story

Biotech News

@FierceBiotech: Angry AstraZeneca investors may hold the only key to a Pfizer deal. Story | Follow @FierceBiotech

@JohnCFierce: If I was counseling Ian Read today, I'd say wipe the smug look off your face, go buy something significant and then break up the co. Pronto. | Follow @JohnCFierce

@DamianFierce: More biotech insider trading as SEC accuses investigators in a halted GTx trial. More | Follow @DamianFierce

@EmilyMFierce: Animal model that mimics hep B, C in humans could spur new treatments. Article | Follow @EmilyMFierce

> Clovis bags 'breakthrough' tag for its cancer drug as ASCO's spotlight awaits. More

> R.I.P.: Merck and Endocyte yank vintafolide app. Item

> Pioneering CAR-T biotech upstart plans to leapfrog into a $115M IPO. News

Pharma Manufacturing News

> FDA sends marshals in to seize drugs from unit of Alkem. More

> Roche investments for boosting manufacturing now exceed $1B. Story

> Novasep gets FDA OK for HPAPI expansion in France. Article

> Abbott expands manufacturing in Latin America with CFR deal. News

> Manufacturing continues to boost WuXi PharmaTech sales. Item

> FDA balks at accepting all EU plant inspections. More

Biotech Research News

> NIH addresses sex bias in preclinical research. Item

> Natural antibacterial clay could fight MRSA, other infections. More

> Anti-MERS therapies ID'd among existing drugs. Story

> Animal model that mimics hep B, C in humans could spur new treatments. Article

> CDC scientist: MERS doesn't present pandemic risk, but other diseases might. More

> Nanocarriers that harness fungus traits could deliver drugs to brain. News

And Finally... The CIA will no longer use vaccination programs as a cover-up for spying operations. More (sub. req.)

Suggested Articles

Stephen Hahn, an oncologist who served as the chief medical officer for the MD Anderson Cancer Center, has secured Senate confirmation as FDA head.

As BMS searches for bright spots in its Opdivo-chemo combo fail from June, it’s zeroing in on squamous lung cancer patients who seemed to benefit.

The FDA's ad watchdog served its most serious violation to Alkermes Wednesday—and it took the unusual step of announcing that violation to the world.